Revolut, the UK fintech, conducts a secondary share sale at a $75 billion valuation, allowing employees to sell up to 20% of their holdings.
Nine former CDC directors warn that RFK Jr.'s leadership jeopardizes public health by undermining science-based policies and replacing experts with unqualified individuals.
Revolut, the UK fintech, conducts a secondary share sale at a $75 billion valuation, allowing employees to sell up to 20% of their holdings.
Nine former CDC directors warn that RFK Jr.'s leadership jeopardizes public health by undermining science-based policies and replacing experts with unqualified individuals.